Secondary effects after SARS-CoV2 vaccination in health care workers (ESVACUNAS)
DOI:
https://doi.org/10.4321/s0465-546x2023000400003Keywords:
secondary effects, vaccine, Covid-19Abstract
Introduction: Currently the only tool we have against COVID-19 are vaccines. In this study we will use the vaccines developed by BioNTech-Pfizer (Comirnaty) and Moderna (Spikevax), and we will carry out an analysis of the side effects they produced by them. The objective of this study is to identify new side effects caused by the aforementioned vaccines among health professionals at the Lozano Blesa University Clinical Hospital in Zaragoza vaccinated from January 16, 2021 to the present, as well as to identify those side effects not included in the leaflets.
Method: Retrospective observational study after administration of the 2nd dose of the vaccine in all health professionals. An anonymous and voluntary questionnaire was conducted asking about side effects after the first and second dose. Data analysis was carried out with the Chi-Square statistical test.
Results: The percentages were obtained: lymphadenopathy 96.4%, dysthermic sensation and chills 96.3%, fever 94.4%, headaches with 90.9%, asthenia 88%, myalgias with 74.4% of the total , others described 3.62%.
Conclusions: Those vaccinated with Moderna presented more symptoms; the necessary values were not reached to determine that there is a statistically significant association in this regard. The symptoms experienced, in a sample that can be extrapolated to the general population, correspond almost entirely to those reflected in the technical specifications of the vaccines developed. It is worth mentioning that the data collected on alterations in menstrual cycles, breastfeeding, or Priapism are symptoms that had not been initially described in the vaccine technical sheets.
Downloads
References
Organización Mundial de la Salud [Internet]. Who. 2020 [citado 20 Abril 2021]. Disponible en: https://www.who.int/es/news/item/07-03-2020-who-statement-on-cases-of-covid-19-surpassing-100-000
Medidas urgentes de prevención, contención y coordinación para hacer frente a la crisis sanitaria ocasionada por el COVID-19. Real Decreto-ley 21/2020, de 9 de junio. Boletín oficial del estado, no 163 (10 de junio 2020)
Estrategia de diagnóstico, vigilancia y control en la fase de transición de la pandemia de covid-19 indicadores de seguimiento. Ministerio de Sanidad 2020.
Estrategia de vacunación covid-19 en España líneas maestras. Ministerio de Sanidad. 2020.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep. 18 de diciembre de 2020;69(50):1922-4.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep. 1 de enero de 2021;69(5152):1653-6.
Guía técnica: Comirnaty 30 μg/dosis (Vacuna Covid-19 ARNm, Pfizer- BioNTech). (27 Enero 2022). https://cima.aemps.es/cima/pdfs/ft/1201528004/FT_1201528004.pdf
Guía técnica: Spikevax (Vacuna Covid-19 ARNm, Moderna). (27 Enero 2022). https://cima.aemps.es/cima/pdfs/ft/1201507001/FT_1201507001.pdf
Edelman A, et al. Association Between Menstrual Cycle Length and Coronavirus Disease 2019 (COVID-19) Vaccination. A U.S. Cohort. Obstet Gynecol. 2022, 5/ene. DOI: 10.1097/AOG.0000000000004695
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021 Oct;21(10):626-636. doi: 10.1038/s41577-021-00592-1. Epub 2021 Aug 9. PMID: 34373623; PMCID: PMC8351583.
Estrategia de vacunación frente a COVID-19 en España (Actualización 8). Ministerio de Sanidad. 2020 12. Enfermedad por coronavirus, COVID-19. Información científica técnica. Ministerio de Sanidad 2022.
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 15 de abril de 2021;384(15):1412-23.
Estrategia de vacunación frente a Covid-19 en España.Grupo de Trabajo Técnico de Vacunación COVID -19, de la Ponencia de Programa y Registro de Vacunaciones. Actualización 5. Marzo 2021.pg[14:15. Disponible en www.sanidad.gob.es/profesionales/.
Maruyama A., Sawa T.; Teramukai S.; Katoh N. Adverse reactions to the first and second doses of Pfizer-BioNTech Covid 19 vaccine among healthcare workers.Journal of infection and Chemotherapy 28 (2022) 934-942.
Chapin-Bardales J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines.JAMA 2021;325:2201-2.https//doi.org/10.1001/jama.2021.5374.
Powell AA, Power L, Westrop S, McOwat K, Campbell H, Simmons R, et al. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England.Euro Surveill 2021;26:2100634. https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100634.
Bae S, Lee YW, Lim SY, Lee J-H, Lim JS, Lee S, et al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Kor Med Sci 2021;36:e115. https://doi.org/10.3346/jkms.2021.36.e115.
Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. Journal of Clinical Medicine. 2021; 10(7):1428. https://doi.org/10.3390/jcm10071428.
Dziedzic A, Riad A, Attia S, Klugar M, Tanasiewicz M. Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe. J Clin Med. 2021;10(22):5338. Published 2021 Nov 16. doi:10.3390/jcm10225338.
Khazeei Tabari MA, Najary S, Khadivi G, Yousefi MJ, Samieefar N, Abdollahimajd F. Oral lesions after COVID-19 vaccination: Immune mechanisms and clinical approach. Infect Med (Beijing). 2022;1(3):171-179. doi: 10.1016/j.imj.2022.06.004.
J. Iwanaga, H. Fukuoka, N. Fukuoka, et al., A narrative review and clinical anatomy of herpes zoster infection following COVID-19 vaccination, Clin. Anat. 35 (1) (2022) 45–51.
Downloads
Published
How to Cite
License
Copyright (c) 2024 Clara Isabel Ferrández Martínez, Marta Redondo Lavirgen, Laura Serrano Barcos
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
